The 2026 Behavioral, Metabolic, and MSK Contracting Playbook

Behavioral Health, Metabolic Care, and MSK/Pain are traditionally contracted separately.Budgets, reporting, and negotiations sit in different silos.

But in 2026, payers and health systems are evaluating these conditions together because they drive the same total cost-of-care trajectory.

Why This Matters

The outcomes that determine cost curve slope are shared:

• Behavioral stability influences adherence and continuity

• Metabolic control shapes long-term chronic risk

• Functional recovery reduces procedure escalation and disability

  
  

Where Fee-for-Service Still Works

• Intake + stabilization phases

• Short-episode therapy or rehab with predictable arc

• Well-defined CPT-based encounters

  
  

Where Fee-for-Service Breaks

• Complex, longitudinal cases requiring continuity

• Care navigation and multi-provider handoffs

• High-acuity populations with churn risk

  
  

The 2026 Model

Contracting still happens in lanes (BH contract / Metabolic contract / MSK contract)but evaluation and renewal leverage are now aggregated.

What payers and systems want:

1. Clear cohort definitions

2. Consistent outcome measurement

3. Claims-linked cost impact

4. Continuity across conditions

   
   

What Scales

Organizations that can:

• Prove improvement across Behavioral, Metabolic, and MSK pathways

• Demonstrate cost curve stabilization

• Support renewal negotiations with economic clarity

  
  

Our Work

We architect commercialization systems that translate clinical improvement into economic credibility for reimbursement negotiations and renewal leverage.

Let’s Architect What’s Next.

TomFounder & Commercialization Architect | Axis Growth Partners

tomriley@axisgrowthpartners.coaxisgrowthpartners.co